Nanostructured lipid carriers for enhanced <i>in vitro</i> and <i>in vivo</i> schistosomicidal activity of praziquantel: effect of charge

Said, Abdelrahman R; Zoghroban, Hager S; Arafa, Mona F.; Mahmoud, Soheir; Maghraby, Gamal M. El

doi:10.1080/03639045.2021.1908339

Cited by 6 publications

(2 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…SEM micrographs demonstrated improved ultrastructural changes in histopathological features of the liver of the S. mansoni-infected mice when compared with other formulations. Tese changes can be attributed to electrostatic interactions that permitted higher concentrations of PQZ to interact more with the worm surface by positively charged PQZ-NLCs [122].…”

Section: Applications Of Nlcsmentioning

confidence: 99%

Nanostructured Lipid Carriers for Improved Delivery of Therapeutics via the Oral Route

Mahor,

Singh,

Gupta

et al. 2023

Journal of Nanotechnology

View full text Add to dashboard Cite

Drug delivery via the oral route has always been challenging for poorly soluble drugs. Acid-induced hydrolysis, enzymatic degradation, and poor mucosal absorbency remain the primary hiccups for effective oral delivery of medications. With the advent of nanotechnology, nanostructured lipid carriers (NLCs) have emerged as a promising delivery carrier that can circumvent gastrointestinal tract (GIT) barriers hindering the solubility and bioavailability of such drugs. These NLCs can efficiently transport drug moieties across intestinal membranes shielding medications from intestinal pH and enzymatic degradation. Because they are composed of lipidic materials, they can be easily absorbed or taken up by various pathways such as transcellular absorption, paracellular transport, and M-cell uptake. Such mechanisms not only improve the absorption and solubility of drugs but also augment bioavailability and residence time and may bypass first-pass metabolism. This review explores the diverse applications of nanostructured lipid carriers (NLCs) in oral drug delivery for various medical conditions, shedding light on their current regulatory status, including FDA-approved options and those in pre/clinical stages. The review also features patented NLC formulations. It provides valuable insights into how NLCs can be harnessed for effective oral drug delivery and outlines recent advancements in optimizing their performance to tackle gastrointestinal barriers, thus opening new possibilities for NLCs in future pharmaceutical applications.

show abstract

Section: Applications Of Nlcsmentioning

confidence: 99%

Nanostructured Lipid Carriers for Improved Delivery of Therapeutics via the Oral Route

Mahor,

Singh,

Gupta

et al. 2023

Journal of Nanotechnology

View full text Add to dashboard Cite

show abstract

“…Results showed that celecoxib-loaded solid lipid nanoparticles were more effective compared to free celecoxib, mainly in mice harboring juvenile parasites, with a worm burden reduction of 86.39%. Said et al (2021) prepared a nanostructured lipid carrier by microemulsification technique to improve the effect of praziquantel evaluated in mice harboring adult worms of S. mansoni. The authors observed that the reduction in the number of ova in the liver was decreased further to reach 90% after administration of praziquantel-loaded nanostructured lipid carriers, compared to praziquantel suspension alone, which caused a reduction of 81%.…”

Section: Nanoformulations For Schistosomiasismentioning

confidence: 99%

Recent approaches in nanocarrier‐based therapies for neglected tropical diseases

Mengarda

Iles

Longo

et al. 2022

WIREs Nanomed Nanobiotechnol

View full text Add to dashboard Cite

Neglected tropical diseases (NTDs) remain major public health problems in developing countries. Reducing the burden of NTDs requires sustained collaborative drug discovery efforts to achieve the goals of the new NTDs roadmap launched by the World Health Organization. Oral drugs are the most convenient choice and usually the safest and least expensive. However, the oral use of some drugs for NTDs treatment has many drawbacks, including toxicity, adverse reactions, drug resistance, drug low solubility, and bioavailability. Since there is an imperative need for novel and more effective drugs to treat the various NTDs, in recent years, several compound‐loaded nanoparticles have been prepared with the objective of evaluating their application as an oral drug delivery system for the treatment of NTDs. This review focuses on the various types of nanoparticle drug delivery systems that have been recently used against the major NTDs caused by parasites such as leishmaniasis, Chagas disease, and schistosomiasis. This article is categorized under: Therapeutic Approaches and Drug Discovery > Nanomedicine for Infectious Disease

show abstract

Fexofenadine-loaded chitosan coated solid lipid nanoparticles (SLNs): A potential oral therapy for ulcerative colitis

El-Dakroury,

Zewail,

Asaad

et al. 2024

European Journal of Pharmaceutics and Biopharmaceutics

View full text Add to dashboard Cite

Nanostructured lipid carriers for enhanced in vitro and in vivo schistosomicidal activity of praziquantel: effect of charge

Cited by 6 publications

References 37 publications

Nanostructured Lipid Carriers for Improved Delivery of Therapeutics via the Oral Route

Nanostructured Lipid Carriers for Improved Delivery of Therapeutics via the Oral Route

Recent approaches in nanocarrier‐based therapies for neglected tropical diseases

Fexofenadine-loaded chitosan coated solid lipid nanoparticles (SLNs): A potential oral therapy for ulcerative colitis

Contact Info

Product

Resources

About